IBE
print


Navigationspfad


Inhaltsbereich

Hoffmann

Dr. rer. biol. hum. Verena Hoffmann, BSc, M.A.

Weitere Informationen

Publikationen

  • Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M.: The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013 Jun 11.
  • Joachim Andrassy, Verena S. Hoffmann, Markus Rentsch, Manfred Stangl, Antje Habicht, Bruno Meiser, Michael Fischereder, Karl-Walter Jauch, and Markus Guba: Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor-Based Immunosuppression? A Systematic Review and Meta-Analysis. Transplantation Journal, Volume 94(12), 27 December 2012, p 1208–1217.
  • Sattler, E.C., Maier, T., Hoffmann, V.S., Hegyi, J., Ruzicka, T. and Berking, C. (2012), Noninvasive in vivo detection and quantification of Demodex mites by confocal laser scanning microscopy. British Journal of Dermatology, 167: 1042–1047.
  • Thomas Büchner, Richard F. Schlenk, Markus Schaich, Konstanze Döhner, Rainer Krahl, Jürgen Krauter, Gerhard Heil, Utz Krug, Maria Cristina Sauerland, Achim Heinecke, Daniela Späth, Michael Kramer, Sebastian Scholl, Wolfgang E. Berdel, Wolfgang iddemann, Dieter Hoelzer, Rüdiger Hehlmann, Joerg Hasford, Verena S. Hoffmann, Hartmut Döhner, Gerhard Ehninger, Arnold Ganser, Dietger W. Niederwieser, and Markus Pfirrmann. Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm—Combined Prospective Analysis by the German AML Intergroup. JCO October 10, 2012 vol. 30 no. 29 3604-3610.
  • Lilli Neumann, Verena S. Hoffmann, Stefan Golgert, Joerg Hasford und Wolfgang von Renteln-Kruse. In-hospital fall-risk screening in 4,735 geriatric patients from the LUCAS project. The Journal of Nutrition, Health & Aging 2012:1-6.
  • Verena Hoffmann, Joerg Hasford, Susanne Saussele, Doris Lindörfer, Markus Pfirrmann, Rüdiger Hehlmann: Der EUTOS Score: Vorhersage von kompletter zytogenetischer Remission und progressionsfreiem Überleben bei CML Patienten unter Imatinibtherapie. Leukämie Rundbrief 16, Dezember 2011: 11-12.
  • Fabian Bamberg, Alexander Becker, Florian Schwarz, Roy P. Marcus, Martin Greif, Franz von Ziegler, Ron Blankstein, Udo Hoffmann, Wieland H. Sommer, Verena S. Hoffmann, Thorsten R. C. Johnson, Hans-Christoph R. Becker, Bernd J. Wintersperger, Maximilian F. Reiser and Konstantin Nikolaou. Detection of Hemodynamically Significant Coronary Artery Stenosis: Incremental Diagnostic Value of Dynamic CT-based Myocardial Perfusion Imaging Radiology September 2011 260:689-698.
  • Joerg Hasford, Michele Baccarani, Verena Hoffmann, Joelle Guilhot, Susanne Saussele, Gianantonio Rosti, François Guilhot, Kimmo Porkka, Gert Ossenkoppele, Doris Lindoerfer, Bengt Simonsson, Markus Pfirrmann and Rudiger Hehlmann. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011 118:686-692.
  • Bamberg F, Sommer W, Hoffmann V, Achenbach S, Nikolaou K, Conen D, Reiser M, Hoffmann U, Becker C. Meta-Analysis and Systematic Review of the Long-Term Predictive Value of Assessment of Coronary Atherosclerosis by Contrast-Enhanced Coronary Computed Tomography Angiography. J Am Coll Cardiol 2011 57: 2426-2436.
  • Stemmler H-J, Stieber P, Lässig D, Bauernfeind I, Fasching P, Beckmann M, Glattes M, Goldmann-Posch U, Hoffmann V, Heinemann V. Follow-Up for Breast Cancer – The Patients View. Breast Care 2006;1:316-319.
  • Stemmler H-J, Stieber P, Bauernfeind I, Kahlert S, Goldmann-Posch U, Hoffmann V, Heinemann V. Die Betroffenen wollen mehr Nachsorge – vor allem apparativ. Frauenarzt 2006; 47 (10): 916-918.